Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

Use of injectable weight loss GLP-1 receptor agonists and the challenges this can pose when prescribing contraception or HRT ...

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...

In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in ...

The endocannabinoid system is one of the most diffuse neurotransmitter systems in the body and the brain. Understanding its ...

Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with ...

Academics from Emory University in Atlanta have found that GLP-1 RAs significantly protect people with type 2 diabetes and ...

GLP-1 receptor agonists may have beneficial effects against Alzheimers, psychiatric and addiction disorders, but early data ...

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed for Type 2 diabetes and obesity owing to their ...